Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: Moderna, Inc. (MRNA)

MRNA insider trades (13 months) →

$228.44 +3.45% vs. previous close · Market cap $91.20B

Quant500 Scores
Momentum
10.0/10
Value
3.0/10
Growth
-
Quality
2.1/10
Multifactor
-

Market and Valuation

Price & Market

Prev Close Price:$220.83
Open:$222.01
Day's Low:$220.23
Day's High:$235.46
Bid / Ask:-
Market Cap:91.20B
Enterprise Value:84.31B

52-Week Range

52-Week Low:$22.28
52-Week High:$254.48
Current position in 52-week range
52w Low-52w High
50-Day Avg:$184.00
200-Day Avg:$87.49

Volume

Volume Today:9,490,033
Avg Volume (3m):21,346,529
Avg Volume (10d):17,942,840
52-Week Change:+829.81%
vs S&P 500, 52 weeks:-
Beta:1.17

Valuation Multiples

P/E (trailing):n/a (loss)

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Jul 31, 2026. With negative EPS a P/E means nothing, so it is not shown.

P/E (forward):-49.82
PEG Ratio:-
Price / Book:13.48
Price / Sales (TTM):40.93
EV / Revenue:37.84
EV / EBITDA:-38.41

Dividends

Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):2.23B
Gross Profit:−1.47B
EBITDA:−2.20B
Net Income (TTM):−3.15B
Rev Growth (YoY):+2.10%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$-7.99

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Jul 31, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$-4.59
Revenue Per Share:$5.66
Cash Per Share:-
Book Value:$16.95
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:5.14B
Total Debt:1.29B
Net Debt (Debt - Cash):−3.85B (net cash)
Debt / Equity:19.04%
Current Ratio:2.30
Quick Ratio:2.07

Cash Flows

Operating Cash Flow:−1.07B
Free Cash Flow (FCF):299.25M
FCF Yield (FCF / Market Cap):-
Enterprise Value:84.31B
EV / Revenue:37.84
EV / EBITDA:-38.41

Profitability

ROE (Return on Equity):-39.00%
ROA (Return on Assets):-13.26%
P/E (trailing):n/a (loss)
P/E (forward):-49.82
Price / Book:13.48
PEG Ratio:-
52-Week Change:+829.81%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$-7.99

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Jul 31, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$-4.59
P/E (forward):-49.82
PEG Ratio:-

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$5.66
Cash Per Share:-
Book Value:$16.95

Cash Flows (TTM)

Free Cash Flow:299.25M
Operating Cash Flow:−1.07B
EBITDA:−2.20B
Total Revenue (TTM):2.23B
Net Income (TTM):−3.15B
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:399,235,889
Float (free shares):371,984,047
Short interest (shares):32,603,398
Short % of float:-
Short Ratio (days to cover):1.86
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

Moderna, Inc. (MRNA) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
8-K2026-09-30View filing ↗
8-K2026-09-01View filing ↗
8-K2026-07-31View filing ↗
8-K2026-07-08View filing ↗
8-K2026-05-11View filing ↗
8-K2026-05-01View filing ↗
ARS2026-03-16View filing ↗
8-K2026-03-05View filing ↗
10-K2026-02-20View filing ↗
8-K2026-02-13View filing ↗

Company and Executive Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

General Information

Headquarters:United States
City:Cambridge
Employees:4,700
Sector:Healthcare
Industry:Biotechnology
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Stéphane Bancel M.B.A.CEO & Director526.14M
Dr. Stephen Hoge M.D.President494.26M
Mr. James M. MockChief Financial Officer482.18M
Ms. Shannon Thyme Klinger J.D.Chief Legal Officer & Corporate Secretary542.18M
Mr. Juan AndresChief Operating Officer601.28M
Ms. Lavina Talukdar CFASenior VP & Head of Investor Relations51-
Chris RidleyVP & Global Head of Communications--
Ms. Tracey FranklinChief People & Digital Technology Officer45-

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Moderna, Inc. (MRNA): Quantitative Analysis

Moderna, Inc. (MRNA) — Healthcare — Biotechnology. MRNA is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, MRNA has returned +674.6% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

Its strongest factor is momentum (Z 3.00, ranked 3 of 494); its weakest is quality (Z -1.72, ranked 468 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Momentum3.0003 of 494 ↑5
Value-1.208488 of 489 =
Quality-1.723468 of 468 =

Market data

MetricValue
Price$228.44
Market Cap91.20B
Forward P/E (estimate)-49.82
Revenue (last 12 months)2.23B
Price / book13.48
Book value per share$16.95
52-week range$22.28 – $254.48
Dividend yield0.00%
Beta1.17
Average volume21,346,529
Shares outstanding399.24M
Short interest (% of float)9.98% (as of Oct 15, 2026)

When does MRNA report earnings? 12 of its last 12, before the open →

What are MRNA insiders doing? 148 transactions filed with the SEC, of them 17 sells, the last one on Oct 15, 2026 →

MRNA latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All MRNA filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Moderna (MRNA)

When does Moderna report earnings?

Moderna has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Jul 31, 2026). MRNA earnings dates and times, quarter by quarter →

Have Moderna insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of Moderna shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 15, 2026, by an officer, for $8.6M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 17 sales by directors, officers and large shareholders. All MRNA insider trades →

What sector is Moderna in, and which index?

Moderna is classified in the Healthcare sector (industry: Biotechnology), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity